Searchable abstracts of presentations at key conferences in endocrinology

ea0049oc3.3 | Receptors & Signalling | ECE2017

AKR1C3-mediated adipose androgen generation drives lipotoxicity in polycystic ovary syndrome

O'Reilly Michael , Kempegowda Punith , Walsh Mark , Taylor Angela , Manolopoulos Konstantinos , Allwood William , Semple Robert , Hebenstreit Daniel , Dunn Warwick , Tomlinson Jeremy , Arlt Wiebke

Polycystic ovary syndrome (PCOS) is prevalent metabolic disorder in women, associated with androgen excess and insulin resistance. These two major features are closely correlated, but the direction of causality remains unclear. Aldoketoreductase type 1C3 (AKR1C3) converts the androgen precursor androstenendione to testosterone (T), and is highly expressed in subcutaneous (SC) adipose tissue. We hypothesised that adipose tissue represents an important site linking androgen acti...

ea0050oc1.3 | Early Career Oral Communications | SFEBES2017

Antioxidant pathway targeting as a therapeutic approach in adrenocortical carcinoma

Chortis Vasileios , Taylor Angela E. , Doig Craig L. , Meimaridou Eirini , Walsh Mark , Jenkinson Carl , Rodriguez-Blanco Giovanny , Jafri Alisha , Ronchi Cristina , Metherell Louise A. , Hebenstreit Daniel , Dunn Warwick B. , Arlt Wiebke , Foster Paul A.

Adrenocortical Carcinoma (ACC) is an aggressive malignancy with poor response to chemotherapy. Here we evaluated a potential new treatment target for ACC, focusing on the mitochondrial NADPH generator Nicotinamide Nucleotide Transhydrogenase (NNT). NNT has a central role within the mitochondrial antioxidant pathways, protecting cells from oxidative stress. Inactivating NNT mutations lead to isolated primary adrenal insufficiency, suggesting a selective vulnerability of adrenoc...

ea0050oc1.3 | Early Career Oral Communications | SFEBES2017

Antioxidant pathway targeting as a therapeutic approach in adrenocortical carcinoma

Chortis Vasileios , Taylor Angela E. , Doig Craig L. , Meimaridou Eirini , Walsh Mark , Jenkinson Carl , Rodriguez-Blanco Giovanny , Jafri Alisha , Ronchi Cristina , Metherell Louise A. , Hebenstreit Daniel , Dunn Warwick B. , Arlt Wiebke , Foster Paul A.

Adrenocortical Carcinoma (ACC) is an aggressive malignancy with poor response to chemotherapy. Here we evaluated a potential new treatment target for ACC, focusing on the mitochondrial NADPH generator Nicotinamide Nucleotide Transhydrogenase (NNT). NNT has a central role within the mitochondrial antioxidant pathways, protecting cells from oxidative stress. Inactivating NNT mutations lead to isolated primary adrenal insufficiency, suggesting a selective vulnerability of adrenoc...

ea0056gp23 | Adrenal clinical | ECE2018

Nicotinamide Nucleotide Transhydrogenase as a novel treatment target in adrenocortical carcinoma

Chortis Vasileios , Taylor Angela , Doig Craig , Walsh Mark , Meimaridou Eirini , Jenkinson Carl , Rodriguez-Blanco Giovanny , Ronchi Cristina , Jaffri Alisha , Metherell Louise , Hebenstreit Daniel , Dunn Warwick , Arlt Wiebke , Foster Paul

Adrenocortical Carcinoma (ACC) is an aggressive malignancy with poor response to chemotherapy. Here we evaluated a potential new treatment target for ACC, focusing on the mitochondrial NADPH generator Nicotinamide Nucleotide Transhydrogenase (NNT). NNT has a central role within mitochondrial antioxidant pathways, protecting cells from oxidative stress. Inactivating human NNT mutations result in congenital adrenal insufficiency. We hypothesized NNT silencing in ACC cells will i...